The absence of a beneficial treatment effect, coupled with an increased incidence of serious bleeding complications, indicates that DrotAA should not be used in patients with severe sepsis who are at low risk for death, such as those with single-organ failure or an APACHE II score less than 25.

Aims The aim of this investigation was to compare the effects of standard (S) with low molecular weight (LMW) heparin on circulating levels of heparin‐binding growth factors (HBGF), known to have angiogenic properties in humans. Methods In two consecutive trials 18 healthy male voluteers were studied on three separate occasions, following a placebo‐controlled crossover design. Subjects were randomised to receive either S‐heparin or LMW heparin or placebo. Heparins were administered either by intravenous (i.v.) or subcutaneous (s.c.) injection and saline placebo by i.v. injection. Serum concentrations of hepatocyte growth factor (HGF), vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor (bFGF) were measured before and up to 24 h after injection. Results Administration of i.v. S‐or LMW‐heparin (50 IU kg−1) resulted in rapid, highly significant (47 fold for S, 30.9 fold for LMW) increases in HGF serum values, reaching maxima of 10.51 ± 1.65 ng ml−1 (S) and 8.28 ± 1.04 ng ml−1 (LMW), respectively, 10 min after drug application. S.c. injection of S‐heparin or LMW heparin resulted in 4.1 and 5.4 fold increases in HGF serum values, respectively. Both agents showed no effects on circulating VEGF or bFGF levels, independent of the route of administration. Conclusions Circulating HGF levels were selectively increased in response to pharmacological doses of two, widely used heparin preparations. This may, in part, explain some of the biological effects of heparin separate from its anticoagulant properties. By this mechanism, the systemic administration of heparin may facilitate collateral vessel formation in various clinical settings of tissue ischaemia.

Cardiovascular disease is the leading cause of death in Western civilization. In this pilot study we evaluated a new method for the diagnosis of myocardial infarction and heart failure by determining the typical fingerprint in the infrared (IR) spectrum of 1 microL of a dried patient serum sample by Fourier transform IR spectroscopy. For classification, cluster analysis and artificial neural networks (ANN) were applied. In this study 567 subjects were enrolled, comprising 225 controls (Co) and 342 patients with myocardial infarction (MI) (n = 157) and heart failure (HF) (n = 185). By applying artificial neural network algorithms, the following sensitivities and specificities of the same spectra were determined: MI versus Co (98%, 97%), HF versus Co (98%, 100%), MI versus HF (100%, 100%), and MI plus HF versus Co (100%, 100%). Based on our data, mid-IR spectroscopy appears to be a promising new method to diagnose heart diseases from serum samples. Artificial neural network algorithms proved to be superior to cluster analysis for correct prediction.